Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172483 | 0.76 | CHRM2 (0.34) | — | |
| SCHEMBL2174224 | 0.72 | MAPK1 (0.30) | — | |
| SCHEMBL2175191 | 0.69 | USP2 (0.36) | KMT2ACTSS | |
| SCHEMBL2172712 | 0.68 | HPGD (0.48) | KMT2A | |
| SCHEMBL25381609 | 0.67 | BTK (0.47) | KMT2AKDM1ACTSK | |
| SCHEMBL31390565 | 0.67 | KDM1A (0.34) | KDM1A | |
| Hydrochloric Acid SCHEMBL2172300 | 0.67 | — | — | |
| SCHEMBL2173732 | 0.65 | GPR119 (0.36) | KMT2AKDM1A | |
| SCHEMBL2175295 | 0.65 | MAPK1 (0.36) | KMT2A | |
| SCHEMBL2173780 | 0.64 | CYP19A1 (0.35) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440958-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2016-09-13 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | KMT2A 1912/4885NPY2R 3904/4885KDM1A 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.